ArticleScientific reports2025
Preparation of a Brucella multiepitope fusion protein based on bioinformatics and its application in serological diagnosis of human brucellosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development of serologic diagnostic test based on in silico predicted synthetic peptides for Brucella canis in dogs.PloS one · 2026Article
- Multiepitope fusion protein-based ELISA for enhanced brucellosis serodiagnosis.PLoS neglected tropical diseases · 2025Article
- Unraveling brucellosis: advances in pathogenesis, diagnostic strategies, therapeutic innovations, and public health perspectives.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Brucellosis is a zoonotic infectious disease caused by the Brucella spp., and the enhancement of diagnostic techniques is imperative for effective disease control. Currently, the diagnosis of brucellosis predominantly relies on serological tests, bacterial culture, and molecular biology methods. Among these approaches, serological diagnosis is the most widely utilized due to its relative simplicity. However, existing diagnostic antigens encounter challenges, such as cross-reactivity. Consequently, the development of novel antigens with high specificity and sensitivity is essential to improve the accuracy and efficiency of serological diagnosis for brucellosis. In this study, five antigenic proteins-Erythritol kinase, Nucleoside diphosphate kinase (NDK), Adenosylhomocysteinase, the 31 kDa immunogenic protein, and Lyso-ornithine lipid O-acyltransferase-were selected, and B-cell linear epitopes were predicted using bioinformatics tools. Four prediction tools, namely ABCpred, SVMTriP, BCPred, and Bepipred Linear Epitope Prediction 2.0, were employed to screen for overlapping candidate epitopes. Fusion proteins were constructed through prokaryotic expression to serve as antigens for serological diagnosis. The sensitivity and specificity of the fusion protein were evaluated using indirect ELISA to detect human IgG antibodies in serum samples. The results indicated that the fusion protein achieved sensitivity and specificity values of 0.8095 and 0.9949, respectively. Although these values were lower in comparison to traditional antigens such as lipopolysaccharide (LPS) and the Rose Bengal antigen, the fusion protein exhibited improved cross-reactivity. This study successfully developed a multiepitope fusion protein for the diagnosis of brucellosis, thereby providing a foundation for the creation of highly specific and sensitive diagnostic antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.